Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bridgebio Pharma Inc
(NQ:
BBIO
)
29.52
-0.57 (-1.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bridgebio Pharma Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Unusual Options Activity Insight: BridgeBio Pharma
August 10, 2021
BridgeBio Pharma (NASDAQ:BBIO) shares experienced unusual...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 06, 2021
Gainers Opiant Pharmaceuticals (NASDAQ:OPNT
Via
Benzinga
BridgeBio Pharma Stock Sees Rising Relative Strength; Still Shy Of Key Threshold
July 01, 2021
In a welcome move, biotech BridgeBio Pharma stock saw its Relative Strength Rating rise from 70 to 73 on Thursday.
Via
Investor's Business Daily
2 Top Biotech Stocks to Buy for Summer 2021
June 05, 2021
Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.
Via
The Motley Fool
BridgeBio Stock Flashes Healthy 83 RS Rating
June 02, 2021
Look for stocks with a Relative Strength Rating of 80 or higher. BridgeBio stock just hit that mark, with a jump from 79 to 83 Wednesday.
Via
Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
June 01, 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...
Via
Benzinga
Exposures
Product Safety
FDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer
June 01, 2021
BridgeBio Pharma Inc (NASDAQ: BBIO), through its affiliate QED Therapeutics Inc and Helsinn Group, has announced FDA approval for Truseltiq (...
Via
Benzinga
Exposures
Product Safety
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
June 01, 2021
From
Helsinn Group
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
May 21, 2021
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.